Gain Therapeutics, Inc.

Gain Therapeutics, Inc. (GANX) priced its initial public offering on Mar 22, 2021 at $11.00 per share, raising $40M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $124.6M. BTIG was lead-left underwriter, joined by Oppenheimer and National. Skadden, Arps advised the company and DLA Piper advised the underwriters.

Gain Therapeutics, Inc. is a development-stage biotechnology company developing treatments for diseases caused by protein misfolding, initially lysosomal storage disorders. Its licensed SEE-Tx platform finds allosteric sites on misfolded proteins and identifies small molecules that bind them to restore protein folding.

Status

IPO

Ticker

GANX

Exchange

Nasdaq Global Market

Priced

Mar 22, 2021

IPO price

$11.00

Raised

$40M

Market cap at IPO price

$124.6M

First filed

Feb 19, 2021

Underwriters

BTIG, Oppenheimer and National

Company counsel

Skadden, Arps

Underwriters' counsel

DLA Piper

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.